AVYCAZ (ceftazidime, avibactam) by AbbVie is [ see clinical pharmacology ( ) ]. Approved for the following infections caused by designated susceptible gram-negative microorganisms in adult, used in combination with metronidazole ( ) complicated urinary tract infections (cuti), including pyelonephritis ( ) hospital-acquired bacterial pneumonia and 19 more indications. First approved in 2015.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AVYCAZ is a fixed-dose combination of ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor) administered intravenously to treat serious gram-negative bacterial infections. It targets resistant pathogens including Pseudomonas aeruginosa, Klebsiella pneumoniae, and Enterobacteriaceae across complicated urinary tract infections, hospital-acquired/ventilator-associated pneumonia, and intra-abdominal infections in adult patients. The avibactam component restores ceftazidime's effectiveness against beta-lactamase-producing organisms.
Established peak-stage product with modest Part D uptake; commercial team likely focused on market maintenance and indication expansion rather than launch acceleration.
[ see Clinical Pharmacology ( ) ].
Worked on AVYCAZ at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moAVYCAZ offers stable, mature-stage career opportunities in commercial execution and hospital-focused sales; however, limited growth trajectory and approaching LOE suggest roles are maintenance-focused rather than entrepreneurial. Career mobility may be enhanced by diversification into indication expansion or early-stage pipeline support.